Who regains the most weight after stopping tirzepatide?
The people who lose the most weight on tirzepatide are the ones who regain it the fastest after stopping. A real-world study of 68 patients found that greater total body weight loss before stopping was the only significant predictor of weight regain [4]. For every additional kilogram lost, the rebound was proportionally larger. In the large SURMOUNT-4 trial, after 36 weeks of treatment and then switching to placebo, 89.5% of those who continued tirzepatide maintained at least 80% of their weight loss, compared to only 16.6% of those who stopped [5]. Within a year of withdrawal, most participants had regained 25% or more of the weight they had lost [3].
The composition of the regained weight is also notable. In a smaller study of 13 participants who stopped tirzepatide, the regained weight was mostly lean mass (67%) rather than fat (38%), and the fat that did return preferentially accumulated in the subcutaneous depot rather than the more harmful visceral fat [1]. This means the body composition after regain may not be as unhealthy as before treatment, but the metabolic benefits—like improved insulin sensitivity—were only partially sustained, reversing by about 42% [1].
Do the metabolic and cardiovascular benefits stick around after stopping?
No, they largely reverse. The SURMOUNT-4 post-hoc analysis showed that the degree of weight regain directly correlated with how much the initial improvements in blood pressure, cholesterol, and blood sugar control were lost [3]. For example, participants who regained 75% or more of their lost weight saw their systolic blood pressure increase by an average of 10.4 mm Hg, their non-HDL cholesterol rise by 10.8%, and their HbA1c (a measure of average blood sugar) increase by 0.35% [3]. Those who managed to keep their weight regain below 25% saw no significant worsening in waist circumference, cholesterol, or fasting insulin [3].
This pattern is confirmed by the systematic review, which concluded that drug withdrawal leads to a partial-to-complete reversal of cardiometabolic improvements [6]. The benefits of tirzepatide are clearly dependent on continued use. The only potential exception is a possible 'carry-over' effect if the drug is stopped well before pregnancy, but even that is fragile and depends on the timing of discontinuation [2].
Is there any benefit to stopping tirzepatide before pregnancy?
Yes, but only if it's done gradually and well in advance. A large multinational study of nearly 900 women found that if tirzepatide or similar drugs were stopped more than 90 days before conception, the risk of gestational diabetes was comparable to women who never took the drugs (16.3% vs. 16.8%) [2]. This was despite a modest rebound in BMI during pregnancy. However, if the drug was stopped abruptly within 90 days of conception, the risk of gestational diabetes jumped by 53% [2]. The study authors attribute this to a steeper, faster weight rebound during early pregnancy. So the 'benefit' here is not from withdrawal itself, but from careful, planned discontinuation that avoids a rapid metabolic rebound during a critical window.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2023 to 2026, 5 from 2024 or later, 5 in Q1 journals, collectively cited 565 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 55 papers retrieved from a database of over 500 million.
Sources used in this answer
1676-P: Changes in Body Composition During and After Weight Loss with Tirzepatide
In a small subset (n=13) of a randomized trial, stopping tirzepatide led to a 42% reversal of weight loss and insulin sensitivity improvements; regained weight was mostly lean mass (67%) and subcutaneous fat, not visceral fat.
Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.
In a large retrospective cohort (n~892), stopping tirzepatide or GLP-1 agonists more than 90 days before conception did not increase gestational diabetes risk, but abrupt discontinuation within 90 days of conception raised the risk by 53%.
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity
In a post-hoc analysis of the SURMOUNT-4 trial (n=308), greater weight regain after tirzepatide withdrawal was associated with progressively worse reversal of improvements in blood pressure, cholesterol, and HbA1c.
1757-P: The Rebound Effect—Weight Regain after Tirzepatide Discontinuation
In a real-world retrospective study (n=68), 72% of patients regained more than 10% of their lost weight within 5 months of stopping tirzepatide; greater total weight loss before discontinuation was the only predictor of more rapid regain.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
In the SURMOUNT-4 randomized withdrawal trial (n=670), continuing tirzepatide maintained 80% of weight loss in 89.5% of participants vs. only 16.6% in those switched to placebo; stopping led to a mean 14% weight regain from week 36 to 88.
EFFICACY OF TIRZEPATIDE ON WEIGHT LOSS, MUSCLE MASS AND CARDIOVASCULAR HEALTH IN THE ADULT POPULATION WITH DIABETES TYPE 2, OVERWEIGHT OR OBESITY: A SYSTEMATIC REVIEW
A systematic review of randomized trials concluded that tirzepatide withdrawal leads to weight regain and a partial-to-complete reversal of cardiometabolic improvements, underscoring the need for chronic maintenance therapy.